Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis

被引：0
|
作者：
Davis, J. C. [1 ]
van der Heijde, D. [2 ]
Braun, D. [3 ]
Dougados, M.
Clegg, D. O. [4 ]
Kivits, A. [5 ]
Fleischmann, R. [6 ]
Inmann, R. [7 ]
Ni, L. [8 ]
Lin, S. [8 ]
Tsuji, W. [8 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Hosp Maastricht, Maastricht, Netherlands
[3] Hosp Cochin, Paris, France
[4] Univ Utah, Ctr Med, Salt Lake City, UT USA
[5] Altoona Ctr Clin Res, Duncansville, TX USA
[6] Univ Texas SW Med Ctr Dallas, Dallas, TX USA
[7] Toronto Western Hosp, Toronto, ON, Canada
[8] Amgen Inc, Thousand Oaks, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：393 / 394
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis
    Baraliakos, Xenofon
    Ganz, Fabiana
    Kameda, Hideto
    Walsh, Jessica
    Jain, Manish
    D'Silva, Kristin
    Wung, Peter
    Bu, Xianwei
    Stigler, Jayne
    Van der Heijde, Desiree
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 825 - 827
  • [42] Aortitis during etanercept therapy for ankylosing spondylitis: Finding the culprit
    Verhoeven, Frank
    Bossert, Marie
    Lohse-Walliser, Anne
    Balblanc, Jean-Charles
    JOINT BONE SPINE, 2012, 79 (05) : 524 - 526
  • [43] Five-year efficacy and safety, including patient-reported outcomes, with etanercept in ankylosing spondylitis
    Mola, E. Martin
    van der Linden, S.
    Wishneski, C.
    Robertson, D.
    Freundlich, B. F.
    Koenig, A. S.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S584 - S585
  • [44] Comparison of healthcare costs in patients with ankylosing spondylitis who received etanercept or infliximab therapy
    Tang, B.
    Rahman, M.
    Meissner, B.
    Thompson, H.
    Karpovich, N.
    Dabbous, O.
    RHEUMATOLOGY, 2008, 47 : II118 - II118
  • [45] Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years
    Baraliakos, Xenofon
    Haibel, Hildrun
    Fritz, Claudia
    Listing, Joachim
    Heldmann, Frank
    Braun, Juergen
    Sieper, Joachim
    ARTHRITIS RESEARCH & THERAPY, 2013, 15 (03)
  • [46] Comparison of healthcare costs in patients with ankylosing spondylitis who received etanercept or infliximab therapy
    Rahman, M.
    Tang, B.
    Meissner, B.
    Thompson, H.
    Dabbous, Q.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 272 - 272
  • [47] Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years
    Xenofon Baraliakos
    Hildrun Haibel
    Claudia Fritz
    Joachim Listing
    Frank Heldmann
    Juergen Braun
    Joachim Sieper
    Arthritis Research & Therapy, 15
  • [48] Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis
    Martin-Mola, E.
    Sieper, J.
    Leirisalo-Repo, M.
    Dijkmans, B. A. C.
    Vlahos, B.
    Pedersen, R.
    Koenig, A. S.
    Freundlich, B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : 238 - 245
  • [49] Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis
    Lee, Y. H.
    Song, G. G.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (08): : 776 - 784
  • [50] Safety of etanercept treatment in patients with hepatitis B or C virus, and rheumatoid arthritis or ankylosing spondylitis
    Moreno, E
    Erra, A
    Leon, Y
    Tomás, C
    Barceló, P
    Marsal, S
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 280 - 280
12345